April 13, 2026 — Penumbra, Inc.  announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone.

April 9, 2026 — Cardiovascular demand continues to rise across the United States, placing increasing pressure on healthcare organizations to maintain access to cardiology care and cardiologists. As workforce constraints persist, healthcare leaders are taking a closer look at how to support coverage, continuity, and long-term care delivery.

April 8, 2026 — Anumana, Inc. recently announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI algorithm for cardiac amyloidosis (CA) — the first and only cleared for this indication using standard 12-lead electrocardiograms (ECGs). The AI-enabled software-as-a-medical-device (SaMD), previously granted FDA Breakthrough Device Designation and selected among the first 15 devices in FDA’s Total Product Life Cycle Advisory Program pilot, is designed to help clinicians identify patients who may be at risk for CA at the point of care.

April 7, 2026 —  BD (Becton, Dickinson and Co.) has launched  the HemoSphere Stream Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients’ blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close gaps between intermittent readings.